| 1 |
33485134 | Expression profiles of HMGB1 on B-CLL related leukocytes contribute to prediction of relapse. | 2021 Jan |
1 |
| 2 |
34638242 | Current and Future Therapies for Immunogenic Cell Death and Related Molecules to Potentially Cure Primary Breast Cancer. | 2021 Sep 23 |
1 |
| 3 |
31727240 | Methods for measuring HMGB1 release during immunogenic cell death. | 2019 |
2 |
| 4 |
27057465 | Immunogenic cell death-related biomarkers: Impact on the survival of breast cancer patients after adjuvant chemotherapy. | 2016 Feb |
1 |
| 5 |
23811849 | Defective immunogenic cell death of HMGB1-deficient tumors: compensatory therapy with TLR4 agonists. | 2014 Jan |
1 |
| 6 |
21602432 | Human tumor cells killed by anthracyclines induce a tumor-specific immune response. | 2011 Jul 15 |
1 |
| 7 |
18353726 | Immunogenicity of anthracyclines: moving towards more personalized medicine. | 2008 Apr |
2 |
| 8 |
17979839 | The interaction between HMGB1 and TLR4 dictates the outcome of anticancer chemotherapy and radiotherapy. | 2007 Dec |
1 |